Objective This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro­pathic pain associated with postherpetic neuralgia (PHN). Research design and methods The 13­week, double­ blind, placebo-­controlled study randomized 370 patients with PHN to pregabalin (150, 300, or 600 mg/day BID) or placebo. Main outcome [...]

Abstract This study was designed to assess the efficacy and safety of pregabalin—a novel a2-d ligand with analgesic, anxiolytic, and anticonvulsant activity—for treating neuropathic pain in patients with post-herpetic neuralgia (PHN). Two hundred and thirty-eight patients were randomised into this multicentre, double-blind, placebo-controlled trial to receive 150 ðn 1⁄4 81Þ; 300 mg/day ðn 1⁄4 [...]